Us Bancorp \De\ Karyopharm Therapeutics Inc. Transaction History

Us Bancorp \De\

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 27, 2022	BUY	$4.08 - $5.82 $10,457 - $14,916	2,563 Added 179.73%	3,989 $22,000
Q2 2022 Aug 01, 2022	SELL	$4.15 - $8.37 $7,482 - $15,091	-1,803 Reduced 55.84%	1,426 $7,000
Q1 2022 May 11, 2022	BUY	$5.91 - $14.38 $2,783 - $6,772	471 Added 17.08%	3,229 $24,000
Q4 2021 Feb 11, 2022	BUY	$5.21 - $8.61 $3,365 - $5,562	646 Added 30.59%	2,758 $18,000
Q3 2021 Nov 10, 2021	BUY	$4.45 - $10.63 $4,187 - $10,002	941 Added 80.36%	2,112 $13,000
Q2 2021 Aug 05, 2021	BUY	$8.11 - $11.11 $8,061 - $11,043	994 Added 561.58%	1,171 $12,000
Q1 2021 Apr 28, 2021	BUY	$9.85 - $17.69 $325 - $583	33 Added 22.92%	177 $2,000
Q2 2020 Aug 07, 2020	SELL	$16.6 - $25.25 $846 - $1,287	-51 Reduced 26.15%	144 $3,000
Q3 2019 Nov 08, 2019	SELL	$5.66 - $11.85 $22,838 - $47,814	-4,035 Reduced 95.39%	195 $2,000
Q2 2019 Aug 13, 2019	BUY	$4.32 - $6.43 $842 - $1,253	195 Added 4.83%	4,230 $25,000
Q1 2019 May 08, 2019	BUY	$4.12 - $10.25 $13,694 - $34,071	3,324 Added 467.51%	4,035 $24,000
Q4 2018 Feb 13, 2019	BUY	$8.2 - $16.95 $5,830 - $12,051	711 New	711 $7,000

56.5M

258K

81.2K

Ticker KPTI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 79,806,600
Market Cap $49.5M
Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

Stay updated on Us Bancorp \De\ with notifications on news.